Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients — Stella

Home/End Stage Renal Disease on Dialysis/

View on ClinicalTrials.gov

Recruiting

Back to End Stage Renal Disease on Dialysis trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

Hong Kong

Chinese University of Hong Kong, Hong Kong

Key details

Phase

Safety & dosing

Sponsor

Chinese University of Hong Kong

Enrollment target

~48 participants

Started

July 2024

Primary completion

July 2026

Age range

18 Years – 75 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.